Akshyaya Pradhan

Dr. Akshyaya Pradhan

Cardiology, King George's Medical University, Lucknow, India
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Indian Heart Journal
Verified
Journal Article
Open access
SGSantanu Guha
Santanu Guha
RSRishi Sethi
Rishi Sethi
SRSaumitra Ray
Saumitra Ray
VBVinay K. Bahl
Vinay K. Bahl
SSS. Shanmugasundaram
S. Shanmugasundaram
VTVijay Trehan
Vijay Trehan

8 February 2024 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
RPRaman Puri
Raman Puri
MBManish Bansal
Manish Bansal
VMVimal Mehta
Vimal Mehta
PDP. Barton Duell
P. Barton Duell
Nathan D. WongNathan D. Wong
Nathan D. Wong
JMJ.C. Mohan
J.C. Mohan
In 2016, the Lipid Association of India (LAI) developed a cardiovascular risk assessment algorithm and defined low-density lipoprotein cholesterol (LDL-C) goals for prevention of atherosclerotic cardiovascular disease (ASCVD) in Indians. The recent refinements in the role of various risk factors and subclinical atherosclerosis in prediction of ASCVD risk necessitated updating the risk algorithm and treatment goals. The LAI core committee held twenty-one meetings and webinars from June 2022 to July 2023 with experts across India and critically reviewed the latest evidence regarding the strategies for ASCVD risk prediction and the benefits and modalities for intensive lipid lowering. Based on the expert consensus and extensive review of published data, consensus statement IV was commissioned. The young age of onset and a more aggressive nature of ASCVD in Indians necessitates emphasis on lifetime ASCVD risk instead of the conventional 10-year risk. It also demands early institution of aggressive preventive measures to protect the young population prior to development of ASCVD events. Wide availability and low cost of statins in India enable implementation of effective LDL-C lowering therapy in individuals at high risk of ASCVD. Subjects with any evidence of subclinical atherosclerosis are likely to benefit the most from early aggressive interventions. This document presents the updated risk stratification and treatment algorithm and describes the rationale for each modification. The intent of these updated recommendations is to modernize management of dyslipidemia in Indian patients with the goal of reducing the epidemic of ASCVD among Indians in Asia and worldwide.

1 July 2018 in Indian Heart Journal
Verified
Journal Article
Open access
SGSantanu Guha
Santanu Guha
HSHarikrishnan Sivadasanpillai
Harikrishnan Sivadasanpillai
SRSaumitra Ray
Saumitra Ray
RSRishi Sethi
Rishi Sethi
SRS. Ramakrishnan
S. Ramakrishnan
YLYash Lokhandwala
Yash Lokhandwala

1 January 2019 in Journal of Family Medicine and Primary Care
Verified
Journal Article
Open access
PDF file
SKSurya Kant
Surya Kant
SSSupriya Sharma
Supriya Sharma
JBJyoti Bajpai
Jyoti Bajpai
PPPankaj K Pathak
Pankaj K Pathak
APAkshyaya Pradhan
Akshyaya Pradhan
PSPriyanka Singh
Priyanka Singh
Tuberculosis (TB) is a chronic infectious disease that can affect various parts of the body including the oral cavity. It primarily affects the lungs. TB bacilli can spread hematogenously to different parts of the body and this also involves maxilla or mandible. Although oral lesions are infrequent, they are crucial for the early diagnosis and interception of primary TB. Intercepting the disease early will limit the morbidity and mortality of the patients. It becomes the responsibility of the dentist to include TB in the differential diagnosis of suspicious oral lesions to prevent delay in the treatment of the disease. It would not be an exaggeration if the dental identification of the TB lesions has the potential of serving as a significant aid in the first line of control for this hazardous and often fatal disease. This article will also emphasize the advancing role of oral pathologists in making the final diagnosis of this dreaded disease.

1 January 2019 in Journal of Family Medicine and Primary Care
Verified
Journal Article
Open access
PDF file
APAkshyaya Pradhan
Akshyaya Pradhan
SVShweta Vohra
Shweta Vohra
PVPravesh Vishwakarma
Pravesh Vishwakarma
RSRishi Sethi
Rishi Sethi
SGLT-2 inhibitors are a novel class of anti-diabetic agents which act by inhibiting glucose reabsorption in proximal convoluted tubules of kidney. Apart from maintaining glucose homeostasis they exert a number of positive effects on the cardiovascular system like weight loss, decreasing blood pressure, preserving renal function, reducing triglycerides, natriuresis and improving endothelial dysfunction. In large clinical trials, all the three prototype agents – Empaglifozin, Canaglifozin and dapaglifozin have shown reductions in major adverse cardiovascular events including cardiovascular deaths, non fatal MI, stroke and heart failure (HF) hospitalizations. The reduction in heart failure hospitalization is a surprising finding and trials of these drug are now underway for HF also. More surprising is the fact that the benefits are comparable or even better that achieved by recently approved novel drugs for HF. In this review, we briefly discuss the pathophysiology of HF in diabetes, describe the prototype SGLT-2 molecules available, their data from large cardiovascular outcome trials till date and their role in current practice of diabetes management.

1 March 2020 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
RPRaman Puri
Raman Puri
VMVimal Mehta
Vimal Mehta
PDP. Barton Duell
P. Barton Duell
DNDevaki Nair
Devaki Nair
JMJagdish Chander Mohan
Jagdish Chander Mohan
RPRaman Puri
Raman Puri